Listing 3 - Actual negotiations

Indication:

In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL that is classified as activated B cell-like (ABC) subtype.

Indication:

Alagille syndrome

Indication:

Ulcerative Colitis

Indication:

Multiple Indications

Indication:

Pulmonary Arterial Hypertension (WHO group 1)

Indication:

Atherosclerotic cardiovascular disease

Indication:

For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum-based chemoradiation therapy (CRT).

Indication:

Multiple Indications

Indication:

Alopecia areata, severe

Indication:

Rett syndrome